RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

May 14 2010

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

To address the need for current education on CRPC, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education lecture series titled Clinical Decision-Making in Castration-Resistant Prostate Cancer. This activity is supported by educational grants from Genentech, sanofi-aventis and Dendreon and is certified for physicians, nurses and pharmacists.

Prostate cancer experts from leading cancer centers across the country will serve as faculty for this activity, which is chaired by Robert Dreicer, MD, MS, FACP, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.